Overexpression of apolipoprotein A-I promotes reverse transport of cholesterol from macrophages to feces in vivo
- PMID: 12900335
- DOI: 10.1161/01.CIR.0000086981.09834.E0
Overexpression of apolipoprotein A-I promotes reverse transport of cholesterol from macrophages to feces in vivo
Abstract
Background: Abundant data indicate that overexpression of apolipoprotein A-I (apoA-I) in mice inhibits atherosclerosis. One mechanism is believed to be promotion of reverse cholesterol transport, but no direct proof of this concept exists. We developed a novel approach to trace reverse transport of labeled cholesterol specifically from macrophages to the liver and feces in vivo and have applied this approach to investigate the ability of apoA-I overexpression to promote macrophage-specific reverse cholesterol transport.
Method and results: J774 macrophages were loaded with cholesterol by incubation with acetylated LDL, labeled with 3H-cholesterol, and then injected intraperitoneally into mice. Plasma and feces were collected at 24 hours and 48 hours, when mice were exsanguinated, tissues were harvested, and all were analyzed for tracer counts. 3H-cholesterol was found in the plasma, liver, and feces. For apoA-I overexpression, mice were injected intravenously with apoA-I adenovirus (1011 particles per animal) 3 days before labeled macrophages were injected. ApoA-I overexpression led to significantly higher 3H-cholesterol in plasma, liver, and feces. The amount of 3H-tracer in the liver was 35% higher (P<0.05) and the 3H-tracer excreted into feces over 48 hours was 63% higher (P<0.05) in apoA-I-expressing mice than in control mice.
Conclusions: Injection of 3H-cholesterol-labeled macrophage foam cells is a method of measuring reverse cholesterol transport specifically from macrophages to feces in vivo, and apoA-I overexpression promotes macrophage-specific reverse cholesterol transport.
Similar articles
-
Overexpression of human apolipoprotein A-II in transgenic mice does not impair macrophage-specific reverse cholesterol transport in vivo.Arterioscler Thromb Vasc Biol. 2005 Sep;25(9):e128-32. doi: 10.1161/01.ATV.0000175760.28378.80. Epub 2005 Jun 30. Arterioscler Thromb Vasc Biol. 2005. PMID: 15994442
-
Expression of cholesteryl ester transfer protein in mice promotes macrophage reverse cholesterol transport.Circulation. 2007 Sep 11;116(11):1267-73. doi: 10.1161/CIRCULATIONAHA.107.704254. Epub 2007 Aug 20. Circulation. 2007. PMID: 17709636
-
Pharmacological activation of liver X receptors promotes reverse cholesterol transport in vivo.Circulation. 2006 Jan 3;113(1):90-7. doi: 10.1161/CIRCULATIONAHA.105.560177. Epub 2005 Dec 19. Circulation. 2006. PMID: 16365197
-
What is so special about apolipoprotein AI in reverse cholesterol transport?Arterioscler Thromb Vasc Biol. 2006 Jan;26(1):12-9. doi: 10.1161/01.ATV.0000194291.94269.5a. Epub 2005 Nov 3. Arterioscler Thromb Vasc Biol. 2006. PMID: 16269660 Review.
-
Endogenous ApoA-I expression in macrophages: A potential target for protection against atherosclerosis.Clin Chim Acta. 2020 Jun;505:55-59. doi: 10.1016/j.cca.2020.02.025. Epub 2020 Feb 21. Clin Chim Acta. 2020. PMID: 32092318 Review.
Cited by
-
Protein-Defined Subspecies of HDLs (High-Density Lipoproteins) and Differential Risk of Coronary Heart Disease in 4 Prospective Studies.Arterioscler Thromb Vasc Biol. 2020 Nov;40(11):2714-2727. doi: 10.1161/ATVBAHA.120.314609. Epub 2020 Sep 10. Arterioscler Thromb Vasc Biol. 2020. PMID: 32907368 Free PMC article.
-
Ezetimibe inhibits hepatic Niemann-Pick C1-Like 1 to facilitate macrophage reverse cholesterol transport in mice.Arterioscler Thromb Vasc Biol. 2013 May;33(5):920-5. doi: 10.1161/ATVBAHA.112.301187. Epub 2013 Mar 7. Arterioscler Thromb Vasc Biol. 2013. PMID: 23471229 Free PMC article.
-
GLUT-1/PKM2 loop dysregulation in patients with non-ST-segment elevation myocardial infarction promotes metainflammation.Cardiovasc Res. 2023 Dec 19;119(16):2653-2662. doi: 10.1093/cvr/cvac184. Cardiovasc Res. 2023. PMID: 36508576 Free PMC article.
-
Hepatic proprotein convertases modulate HDL metabolism.Cell Metab. 2007 Aug;6(2):129-36. doi: 10.1016/j.cmet.2007.07.009. Cell Metab. 2007. PMID: 17681148 Free PMC article.
-
Low apolipoprotein A1 was associated with increased risk of cancer mortality in patients following percutaneous coronary intervention: A 10-year follow-up study.Int J Cancer. 2022 Nov 1;151(9):1482-1490. doi: 10.1002/ijc.34164. Epub 2022 Jul 7. Int J Cancer. 2022. PMID: 35796324 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical